PubRank

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Clinical Trial ID NCT01585415

PubWeight™ 14.20‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01585415

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 45.46
2 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008 10.13
3 Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010 4.71
4 Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014 1.47
5 Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014 1.33
6 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013 1.31
7 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
8 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
9 BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012 1.04
10 BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015 0.99
11 Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep 2012 0.97
12 Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014 0.95
13 Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013 0.95
14 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
15 Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology 2015 0.84
16 Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 2015 0.82
17 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
Next 100